Role of High-Volume Plasmapheresis in the Management of Paediatric Acute Liver Failure

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032951

Enrollment

Registered

2023-10-30

Start date

2022-11-22

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

K72.0

Interventions

Group 1: Children with acute liver failure (PALF) according to PALF Study Group criteria (Squires RH et al, 2006) treated with high-volume plasmapheresis (HVP) between 2012 and 2023. Monocentric, retr

Eligibility

Sex/Gender

All

Age

No minimum to 17 Years

Inclusion criteria

Inclusion criteria: Treatment with high-volume plasmapheresis in children with pediatric acute liver failure according to PALF Study Group criteria: - Acute hepatocellular damage with elevated transaminases. - No pre-existing chronic liver disease - INR = 1.5* in the presence of hepatic encephalopathy (HE) - INR = 2.0* with or without HE (* after i.v. vitamin K administration)

Exclusion criteria

Exclusion criteria: missing documentation

Design outcomes

Primary

Measure	Time frame
Aim of the study is to report on feasibility and safety of HVP in PALF	—

Secondary

Measure	Time frame
Furthermore, efficacy and outcome will be analyzed.	—

Countries

Germany

Contacts

Public ContactJohannes Hilberath

Universitätskinderklinik Tübingen

johannes.hilberath@med.uni-tuebingen.de+49 7071 81328

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026